文献速递腹部技术与安全US

使用超声造影监测LI-RADS 2017版3/4类结节的恶性进展

Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
PubMed 文献 · Eur Radiol · 2023-07-05

该研究随访了192例患者的245个基线超声及超声造影(CEUS)判为LR-3/4的肝结节,分析CEUS LI-RADS亚分类(P1-P7)的进展率与时间。LR-3结节40.3%、LR-4结节78.9%最终进展为HCC,LR-4累积进展率显著高于LR-3(p < 0.001)。CEUS特征、LI-RADS分类及结节变化是进展为HCC的风险因素。

要点

  • LR-4结节进展为HCC的比例为78.9%,高于LR-3的40.3%,累积进展率显著更高(p < 0.001)。
  • 同时具有动脉期高增强和晚期轻度廓清的结节进展率为100%。
  • 亚分类P1(LR-3a)进展率更低(38.0% vs. 47.6-100.0%)、中位进展时间更晚(25.1个月 vs. 2.0-16.3个月)。

核心结论

  • CEUS是监测有HCC风险结节的有用工具,CEUS特征、LI-RADS分类及结节变化为LR-3/4结节的进展提供有用信息。

研究设计与样本

  • 回顾性分析2010年1月至2016年12月192例患者的245个基线US及CEUS判为LR-3/4的肝结节,随访至进展为HCC,采用单因素及多因素Cox比例风险模型分析风险因素。

关键影像表现/征象

  • 动脉期高增强(APHE)结节的进展率为81.2%,晚期轻度廓清结节为64.7%,同时具有两种特征者为100%。
  • LR-3结节最终进展为HCC的比例为40.3%,LR-4结节为78.9%。
  • 亚分类P1(LR-3a)的总体进展率为38.0%,低于其他亚分类的47.6-100.0%;中位进展时间为25.1个月,晚于其他亚分类的2.0-16.3个月。
  • LR-3a(P1)、LR-3b(P2/3/4)和LR-4(P5/6/7)的累积进展率分别为38.0%、52.9%和78.9%。

诊断标准与关键数值

  • CEUS LI-RADS亚分类:P1对应LR-3a,P2/3/4对应LR-3b,P5/6/7对应LR-4。
  • 进展为HCC的风险因素包括:可视化评分B/C、CEUS特征(APHE、廓清)、LR-4分类、回声改变及明确增大。

临床应用与阅片要点

  • 对于基线US及CEUS判为LR-3/4的结节,可依据CEUS LI-RADS亚分类(P1-P7)及CEUS特征(APHE、廓清)评估恶性进展风险。
  • 随访中需关注结节的可视化评分、回声改变及明确增大,这些因素与进展为HCC相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To identify the risk factors for predicting the malignant progression of LR-3/4 observations on the baseline and contrast-enhanced ultrasound (CEUS).

METHODS: In total, 245 liver nodules assigned to LR-3/4 in 192 patients from January 2010 to December 2016 were followed up by baseline US and CEUS. The differences in the rate and time of progression to hepatocellular carcinoma (HCC) among subcategories (defined as P1-P7) of LR-3/4 in CEUS Liver Imaging Reporting and Data System (LI-RADS) were analyzed. The risk factors to predict progression to HCC were analyzed by univariate and multivariate Cox proportional hazard model analysis.

RESULTS: A total of 40.3% of LR-3 nodules and 78.9% of LR-4 nodules eventually progressed to HCC. The cumulative incidence of progression was significantly higher for LR-4 than LR-3 (p < 0.001). The rate of progression was 81.2% in nodules with arterial phase hyperenhancement (APHE), 64.7% in nodules with late and mild washout, and 100% in nodules with both characteristics. The overall progression rate and median progression time of subcategory P1 nodules (LR-3a) were lower (38.0% vs. 47.6-100.0%) and later (25.1 months vs. 2.0-16.3 months) than those of other subcategories. The cumulative incidence of progression of LR-3a (P1), LR-3b (P2/3/4), and LR-4 (P5/6/7) categories were 38.0%, 52.9%, and 78.9%. The risk factors of HCC progression were Visualization score B/C, CEUS characteristics (APHE, washout), LR-4 classification, echo changes, and definite growth.

CONCLUSION: CEUS is a useful surveillance tool for nodules at risk of HCC. CEUS characteristics, LI-RADS classification, and changes in nodules provide useful information for the progress of LR-3/4 nodules.

CLINICAL RELEVANCE STATEMENT: CEUS characteristics, LI-RADS classification, and nodule changes provide important predictions for LR-3/4 nodule progression to HCC, which may stratify the risk of malignant progression to provide a more optimized and refined, more cost-effective, and time-efficient management strategy for patients.

KEY POINTS: • CEUS is a useful surveillance tool for nodules at risk of HCC, CEUS LI-RADS successfully stratified the risks that progress to HCC. • CEUS characteristics, LI-RADS classification, and changes in nodules can provide important information on the progression of LR-3/4 nodules, which may be helpful for a more optimized and refined management strategy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Huang, Li, He, et al. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound. Eur Radiol. 2023. PMID: 37405501. doi:10.1007/s00330-023-09811-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。